根据《中华人民共和国公司法》《上市公司治理准则》《深圳证券交易所上市 公司自律监管指引第 2 号——创业板上市公司规范运作》等有关规定，杭州泰格 医药科技股份有限公司（以下简称"公司"）董事会审计委员会现将对立信会计师事 务所（特殊普通合伙）（以下简称"立信"）以及香港立信德豪会计师事务所（以下 简称"立信德豪"）履行监督职责的情况汇报如下： 杭州泰格医药科技股份有限公司 董事会审计委员会对会计师事务所履行监督职责情况报告 一、2023 年年审会计师事务所基本情况 1、会计师事务所基本情况 立信会计师事务所（特殊普通合伙）由我国会计泰斗潘序伦博士于1927年在上 海创建，1986年复办，2010年成为全国首家完成改制的特殊普通合伙制会计师事务 所，注册地址为上海市黄浦区南京东路61号4楼。立信是国际会计网络BDO的成员 所，长期从事证券服务业务，新证券法实施前具有证券、期货业务许可证，具有H 股审计资格，并已向美国公众公司会计监督委员会（PCAOB）注册登记。 香港立信德豪会计师事务所成立于1981年，注册地为香港。立信德豪是国际会 计网络BDO的成员所，具备审计依据国际财务报告准则编制的上市公司财务报告的 ...

智通财经APP讯，泰格医药(03347)发布公告，于2024年3月28日，第五届董事会第六次会议和第五届监 事会第四次会议审议通过了《关于终止实施2022年A股限制性股票激励计划并作废限制性股票的议 案》，决定终止实施本激励计划，对于已授予但尚未归属的限制性股票全部作废，与之配套的《公司 2022年A股限制性股票激励计划实施考核管理办法》等相关文件一併终止。 公司前述两次通过集中竞价交易方式回购用于实施员工持股计划或A股股权激励计划的股份746.965万股 未能使用。根据公司回购股份方案及《深圳证券交易所上市公司自律监管指引第9号—回购股份》相关 规定，鉴于公司回购的股份预计无法用于实施A股股权激励或员工持股计划，公司拟将存放于回购专用 账户的746.965万股进行注销，并相应减少公司注册资本。 ...

Core Insights - The company reported a revenue of 7.384 billion yuan for 2023, representing a year-on-year growth of 4.2% [1] - Gross profit was approximately 2.821 billion yuan, with a year-on-year increase of 1.3% [1] - Net profit attributable to shareholders was 2.0265 billion yuan, up 0.5% year-on-year, while adjusted net profit reached 1.786 billion yuan, reflecting a 7.2% increase [1] - Earnings per share stood at 2.34 yuan, with a final dividend of 5.68 yuan for every 10 shares [1] Revenue Breakdown - Revenue from China amounted to 4.2345 billion yuan, marking a significant year-on-year growth of 17.6%, driven by the company's leading position in the Chinese clinical services market and increased revenue from clinical trials for drugs and medical devices [1] - The company experienced rapid growth in on-site management and patient recruitment services in 2023 [1] - Revenue from data management, statistical analysis, scientific affairs, medical imaging, real-world research, and pharmacovigilance services also saw steady growth in 2023 [1] - Conversely, overseas revenue was 3.1495 billion yuan, showing a decline of 9.6%, primarily due to reduced income from multi-regional clinical trials related to COVID-19 vaccines during the reporting period [1] Business Development - The company recorded a net new order amount of 7.852 billion yuan in 2023, which represents a year-on-year decline of 18.8% [1] - The decrease in new orders was attributed to some clients canceling previous orders in the fourth quarter of 2023 or experiencing negative changes during project execution [1] - Additionally, the handling fees for new orders saw a significant year-on-year decline in 2023 [1]

Financial Performance - Total revenue for the year ended December 31, 2023, was RMB 7,384.0 million, representing a 4.2% increase from RMB 7,085.5 million in 2022[2] - Adjusted net profit attributable to the company's owners increased by 7.2% to RMB 1,786.0 million from RMB 1,665.8 million in the previous year[2] - The company's net profit for the year decreased by 5.7% year-on-year from RMB 2,281.3 million to RMB 2,151.6 million, primarily due to increased sales costs and marketing expenses[47] - The profit attributable to the company's owners for 2023 was RMB 2,026.5 million, slightly up from RMB 2,016.1 million in 2022[52] - The company's gross profit was RMB 2,820.6 million, slightly up from RMB 2,785.4 million, with a gross margin decrease from 39.3% to 38.2%[35] - The company's total equity rose to RMB 24,453,562,000, an increase of 7.82% from RMB 22,681,028,000 in 2022[145] - The company's total assets as of December 31, 2023, amounted to RMB 25,542,006 thousand, up from RMB 23,716,941 thousand in 2022, reflecting a growth of 7.71%[134] Revenue Breakdown - Revenue from clinical trial-related services and laboratory services increased by 8.6% year-on-year, reaching RMB 3,215.9 million[19] - Revenue from the company's operations in China grew by 17.6% year-on-year, amounting to RMB 4,234.5 million, driven by its leading position in the clinical services market[19] - Revenue from clinical trial technical services was RMB 4,168,128,000, up from RMB 4,125,199,000, reflecting a growth of 1.04%[150] - Revenue from clinical trial related services and laboratory services increased significantly to RMB 3,215,911,000, a rise of 8.59% from RMB 2,960,272,000 in 2022[150] Assets and Liabilities - Total assets rose by 8.1% to RMB 29,680.7 million, compared to RMB 27,446.5 million in 2022[3] - The company's trade receivables and other receivables increased by 20.4% to RMB 1,428.2 million, driven by growth in business activities[59] - The company's contract assets rose by 18.4% to RMB 2,364.4 million, reflecting an increase in total contract amounts with clients[61] - The company's outstanding borrowings reached RMB 2,800.6 million as of December 31, 2023, with RMB 2,366.4 million classified as short-term borrowings[72] - The debt-to-equity ratio was reported at 11.5% as of December 31, 2023[73] Investments and Acquisitions - The company plans to enhance its end-to-end service capabilities and expand its global market share through mergers and acquisitions and by establishing business units based on therapeutic areas[11] - The company has committed additional capital of RMB 7.5 billion to invest in Hangzhou Taikun, a joint venture, as of December 31, 2023[77] - The company is a strategic investor in 170 innovative companies in the healthcare sector and a limited partner in 55 professional investment funds as of December 31, 2023[68] - The company plans to continue selective acquisitions and investments to achieve business growth, but failure to identify suitable targets or implement transactions successfully could adversely affect its financial performance[107] Research and Development - Research and development expenses increased by 11.5% year-on-year from RMB 234.6 million to RMB 261.6 million, attributed to a rise in the number of employees involved in R&D activities and their compensation[43] - The company has established integrated R&D service platforms for both pharmaceuticals and medical devices, covering the entire lifecycle of product development[85] - The company is investing heavily in R&D, with a budget allocation of 20 million USD for the development of new technologies[190] Market Trends and Outlook - The global pharmaceutical market is projected to reach approximately $1.6 trillion in 2023 and is expected to grow to $1.9 trillion by 2027, driven by aging populations and rising chronic non-communicable diseases[92] - The company anticipates further improvement in industry trends and the macro environment in the upcoming year[9] - Future outlook indicates a projected revenue growth of 15% for the upcoming fiscal year, driven by new product launches and market expansion strategies[190] Compliance and Governance - The company has adopted the principles and provisions of the corporate governance code and has complied with its provisions during the reporting period[115] - The board approved a proposal to change the use of proceeds to better allocate financial resources and seize domestic market opportunities[120] - The company is committed to adhering to international financial reporting standards to ensure transparency and accuracy in financial reporting[188] Employee and Talent Management - The total number of employees increased from 9,455 as of June 30, 2023, and 9,233 as of December 31, 2022, to 9,701 as of December 31, 2023[38] - Attracting, training, motivating, and retaining skilled personnel is essential for the company's success, especially in the competitive pharmaceutical and medical device sectors[108] - The company acknowledges the limited supply of qualified personnel in the industry, necessitating competitive compensation and benefits to attract and retain talent[108] Risks and Challenges - The company faces risks from potential natural disasters, pandemics, and regulatory changes that could impact operations and financial performance[99][101] - Increased competition in the global clinical contract research organization market may pressure pricing and affect revenue and profitability[101] - The company faces risks related to obtaining and renewing necessary regulatory approvals, licenses, and certifications, which are critical for its operations[105]

证券代码：300347 证券简称：泰格医药 公告编码（2024）009 号 杭州泰格医药科技股份有限公司 2024 年第一次临时股东大会决议的公告 公司及董事会全体成员保证公告内容的真实、准确和完整，对公告的虚假记载、误导性陈述或者 重大遗漏负连带责任。 特别提示： 1、本次股东大会未出现否决议案的情形。 一、会议召开情况 1、会议召开时间 现场会议召开时间为：2024年3月21日（星期四）下午15：00 网络投票时间：2024年3月21日 其中，通过深圳证券交易所交易系统进行网络投票的具体时间为2024年3月21日上午9： 15—9：25，9：30—11：30和下午13：00—15：00；通过深圳证券交易所互联网投票系统进 行网络投票的具体时间为2024年3月21日上午9：15至2024年3月21日下午15：00的任意时间。 2、现场会议召开地点：杭州市滨江区聚工路19号盛大科技园A座18楼会议室 3、会议方式：本次股东大会采取现场投票和网络投票相结合的方式 4、召集人：杭州泰格医药科技股份有限公司董事会 5、现场会议主持人：公司董事长叶小平先生 6、本次股东大会会议的召集、召开与表决程序符合《公司法》、《 ...

北京市嘉源律师事务所 关于杭州泰格医药科技股份有限公司 2024 年第一次临时股东大会的法律意见书 西城区复兴门内大街 158 号远洋大厦 4 楼 中国 · 北京 EUM == 177 YUAN LAW OFFICES 北京 BEIJING · 上海 SHANGHAI · 深圳 SHENZHEN · 香港 HONG KONG · 广州 GUANGZHOU · 西安 XI'AN 致:杭州泰格医药科技股份有限公司 北京市嘉源律师事务所 关于杭州泰格医药科技股份有限公司 2024 年第一次临时股东大会的法律意见书 嘉源(2024)-04-179 受杭州泰格医药科技股份有限公司(以下简称"公司")委托,北京市嘉源律 师事务所(以下简称"本所")指派律师出席公司 2024年第一次临时股东大会(以 下简称"本次股东大会"),并依据《中华人民共和国公司法》(以下简称"《公 司法》"）、《上市公司股东大会规则》(以下简称"《股东大会规则》")、《杭 州泰格医药科技股份有限公司章程》(以下简称"《公司章程》")及《杭州泰格 医药科技股份有限公司股东大会议事规则》(以下简称"《议事规则》")的规定, 就公司本次股东大会的召集、召 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 香港，二零二四年三月十八日 於本公告日期，執行董事為葉小平博士、曹曉春女士、吳灝先生及聞增玉先生； 獨立非執行董事為楊波博士、廖啟宇先生及袁華剛先生。 （股份代號：3347） 董事會會議召開日期 杭州泰格醫藥科技股份有限公司（「本公司」）董事（「董事」）會（「董事會」）謹此宣 佈，董事會會議將於二零二四年三月二十八日（星期四）舉行，藉以（其中包括）審 議及批准本公司及其附屬公司截至二零二三年十二月三十一日止年度的全年業績 及其刊發，以及考慮建議派發末期股息（如適用）。 承董事會命 杭州泰格醫藥科技股份有限公司 葉小平 董事長 HANGZHOU TIGERMED CONSULTING CO., LTD. 杭州泰格醫藥科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） ...

Core Viewpoint - The pharmaceutical sector in Hong Kong and A-shares experienced a significant surge, particularly in innovative drugs, medical services, and CROs, driven by market speculation regarding supportive government policies for innovative drug development [1][3]. Group 1: Market Performance - A-shares in innovative drugs saw substantial gains, with companies like Tigermed and Shouyao Holdings hitting the 20% daily limit, while others like Zhaoyan New Drug and Aosaikang also reached their daily limits [1][2]. - The Hong Kong innovative drug sector, led by Tigermed, rose over 20%, with Zhaoyan New Drug increasing nearly 16% [2][3]. Group 2: Policy and Market Drivers - A draft proposal for comprehensive support for innovative drug development has circulated, aiming to enhance R&D, approval, usage, and payment processes, although it has not been officially confirmed [3]. - The 2024 government work report highlighted "innovative drugs" for the first time, signaling potential policy support that could enhance the competitiveness and innovation of the sector [3]. - Upcoming international conferences like AACR and ASCO are expected to act as catalysts for the innovative drug sector [3]. Group 3: Industry Growth and Internationalization - China has developed a competitive edge in certain innovative drug areas, with 5,033 drug pipelines under development, representing 23.6% of the global total, second only to the U.S. [4]. - The number of innovative drugs going international has been increasing, with nearly 200 projects from 2020 to 2023, averaging about 50 per year, indicating growing global recognition [4]. - In early 2024, overseas licensing transactions reached $9.146 billion, surpassing the total for 2020, marking a potential breakout year for innovative drugs going international [4]. Group 4: Valuation and Investment Opportunities - The pharmaceutical sector's valuation is currently below 40% of historical averages since 2005, suggesting limited downside potential even if valuations decline further [4]. - Analysts are optimistic about the innovative drug sector's valuation and potential, highlighting the importance of internationalization and government support in driving growth [4][5]. - Investment recommendations include focusing on overseas breakthroughs in specific therapeutic areas and identifying leading companies poised for recovery and international expansion, such as Innovent Biologics and WuXi Biologics [5].

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2024年2月29日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 杭州泰格醫藥科技股份有限公司 呈交日期: 2024年3月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | A | | 於香港聯交所上市 (註1) | | 否 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 | 300347 | 說明 | 於深圳證券交易所上市 | | | | | | | | | 法定/註冊股份數目 | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 749,293,420 RMB | | | 1 RMB | | 749,293,420 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 749,293,420 RMB | | | 1 RMB | | 749,293,420 | | 2. 股份分類 | 普通股 | H 股份類別 ...

3．会议召开的合法、合规性：经公司第五届董事会第五次会议审议通过，决定召开 2024年第一次临时股东大会，召集程序符合有关法律、行政法规、部门规章、规范性文件 和公司章程的规定。 证券代码：300347 证券简称：泰格医药 公告编码（2024）008 号 杭州泰格医药科技股份有限公司 关于召开 2024 年第一次临时股东大会的公告 公司及董事会全体成员保证公告内容的真实、准确和完整，对公告的虚假记载、误导性陈述或者 重大遗漏负连带责任。 一、召开会议的基本情况 1．股东大会届次：2024年第一次临时股东大会。 2．股东大会的召集人：公司董事会。 4．会议召开的日期、时间： 现场会议召开日期和时间：2024 年3 月21 日（星期四）下午 15:00 点 网络投票日期和时间： （1）通过深圳证券交易所交易系统进行网络投票的时间为：2024 年 3 月 21 日上午 9:15—9:25，9:30—11:30 和下午13:00-15:00； （2）通过深圳证券交易所互联网投票系统投票的具体时间为：2024 年3 月21 日上午 9:15 至 2024 年3 月21 日下午15:00。 5．会议的召开方式：本次股东大 ...